ホルモン避妊薬市場：ホルモン、避妊法、エンドユーザー別-2025～2030年の世界予測

ホルモン避妊薬市場は、2023年に171億9,000万米ドルと評価され、2024年には183億4,000万米ドルに達すると予測され、CAGR 6.76％で成長し、2030年には271億9,000万米ドルに達すると予測されています。

ホルモン避妊薬の市場範囲には、女性の体内のホルモンレベルを調整することで妊娠を予防するさまざまな方法が含まれます。これには、経口ピル、注射、パッチ、膣リング、インプラントなどが含まれます。ホルモン避妊薬の用途は主に避妊を対象としているが、月経周期の調整、多嚢胞性卵巣症候群（PCOS）のような症状の管理、にきびの軽減といった利点もあります。最終用途は個人消費者と医療施設にまたがります。市場の成長は、家族計画に対する意識の高まり、月経関連疾患の有病率の上昇、近代的避妊法の受け入れ拡大によって促進されます。新たなビジネス機会は、避妊教育や避妊サービスに対するニーズが満たされていない地域や、副作用を最小限に抑える先進的デリバリーシステムの開発にあります。非侵襲的な避妊薬や有効期間を延長した避妊薬などの技術革新に注力する企業は、大きな市場シェアを獲得できる可能性があります。一方、課題としては、文化的・宗教的な反対、一貫した使用の必要性、ホルモン法に伴う副作用、非ホルモン代替品との競合などが挙げられます。規制上のハードルも製品発売を遅らせ、市場力学に影響を与える可能性があります。制限要因としては、低所得地域における価格への敏感さや、入手可能性や承認に影響する国のポリシーの違いが挙げられます。個別化医療や遺伝子プロファイリングのような技術的進歩は技術革新の道を提供し、ホルモン投与量を最適化した標的避妊ソリューションを可能にすることで、有効性の向上と副作用の軽減を実現します。同市場は、人口統計動向、消費者行動、ニーズに合わせたマーケティング戦略に関する洞察から利益を得ることができます。ホルモン避妊薬市場の性質は競争的で日進月歩であるため、企業は消費者の嗜好の変化や科学的開拓に迅速に対応する必要があります。手頃な価格、入手しやすさ、ホルモン避妊の利点と欠点に関する包括的な教育キャンペーンのバランスを維持することが、サステイナブル成長にとって極めて重要です。

市場力学：急速に進化するホルモン避妊薬市場の主要市場洞察を公開

ホルモン避妊薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネス機会の獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 女性における妊娠関連の健康リスク事例の増加
  • 避妊薬の使用を促進する政府の取り組み
  • 経口避妊薬のオンライン入手可能性
• 市場抑制要因
  • ホルモン避妊薬の副作用
• 市場機会
  • 効果の高い避妊法を生み出すための研究
  • ホルモン避妊薬の広告とマーケティングの改善
• 市場課題
  • ホルモン避妊薬の限定的な社会的受容

ポーターのファイブフォース：ホルモン避妊薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、ホルモン避妊薬市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ホルモン避妊薬市場における外部からの影響の把握

外部マクロ環境要因は、ホルモン避妊薬市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：ホルモン避妊薬市場における競合情勢の把握

ホルモン避妊薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：ホルモン避妊薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ホルモン避妊薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：ホルモン避妊薬市場における成功への道筋を描く

ホルモン避妊薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 妊娠に関連した女性の健康リスクの増加
    • 避妊具の使用を促進する政府の取り組み
    • 経口避妊薬のオンライン購入
  • 抑制要因
    • ホルモン避妊薬の副作用
  • 機会
    • 非常に効果的な避妊法を開発するための研究
    • ホルモン避妊薬の広告とマーケティングの改善
  • 課題
    • ホルモン避妊薬の社会的受容は限られている
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 ホルモン避妊薬市場：ホルモン別

• イントロダクション
• アンドロゲン
• 抗アンドロゲン
• エストロゲン
• ゴナドトロピン
• プロゲストーゲン

第7章 ホルモン避妊薬市場：避妊法別

• イントロダクション
• 複合経口避妊薬
• 埋込型避妊具
• 注射による避妊
• 子宮内
• 経口避妊薬
• 経皮パッチ
• 膣リング

第8章 ホルモン避妊薬市場：エンドユーザー別

• イントロダクション
• 外来手術センター
• 婦人科センター
• 在宅医療
• 病院・クリニック

第9章 南北アメリカのホルモン避妊薬市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋のホルモン避妊薬市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのホルモン避妊薬市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Afaxys Pharma, LLC
• Agile Therapeutics
• Amgen Inc.
• Bayer AG
• Boehringer Ingelheim GmbH
• Cipla Limited
• Glenmark Pharmaceuticals Limited
• HLL Lifecare Limited
• Johnson & Johnson Services, Inc.
• Lupin Pharmaceuticals, Inc.
• Novartis AG
• Pfizer, Inc.
• Piramal Group
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. HORMONAL CONTRACEPTIVES MARKET RESEARCH PROCESS
• FIGURE 2. HORMONAL CONTRACEPTIVES MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. HORMONAL CONTRACEPTIVES MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. HORMONAL CONTRACEPTIVES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HORMONAL CONTRACEPTIVES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HORMONAL CONTRACEPTIVES MARKET DYNAMICS
• TABLE 7. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ANDROGENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ANTIANDROGENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ESTROGENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY GONADOTROPINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY PROGESTOGENS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY COMBINED ORAL CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY IMPLANTED CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INJECTED CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY INTRAUTERINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY ORAL CONTRACEPTIVES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY TRANSDERMAL PATCH, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY VAGINAL RING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY GYNECOLOGY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. CANADA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 37. CANADA HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 38. CANADA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 54. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 55. CHINA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. INDIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 57. INDIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 58. INDIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 60. INDONESIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 61. INDONESIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 63. JAPAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 64. JAPAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 66. MALAYSIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 67. MALAYSIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 69. PHILIPPINES HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 70. PHILIPPINES HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 72. SINGAPORE HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 73. SINGAPORE HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 75. SOUTH KOREA HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 76. SOUTH KOREA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 78. TAIWAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 79. TAIWAN HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 81. THAILAND HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 82. THAILAND HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 84. VIETNAM HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 85. VIETNAM HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 91. DENMARK HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 92. DENMARK HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 94. EGYPT HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 95. EGYPT HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 97. FINLAND HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 98. FINLAND HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 100. FRANCE HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 101. FRANCE HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 103. GERMANY HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 104. GERMANY HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 106. ISRAEL HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 107. ISRAEL HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. ITALY HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 109. ITALY HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 110. ITALY HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 112. NETHERLANDS HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 113. NETHERLANDS HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 115. NIGERIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 116. NIGERIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 118. NORWAY HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 119. NORWAY HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. POLAND HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 121. POLAND HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 122. POLAND HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. QATAR HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 124. QATAR HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 125. QATAR HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 127. RUSSIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 128. RUSSIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 130. SAUDI ARABIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 131. SAUDI ARABIA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH AFRICA HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 136. SPAIN HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 137. SPAIN HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 139. SWEDEN HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 140. SWEDEN HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 142. SWITZERLAND HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 143. SWITZERLAND HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 145. TURKEY HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 146. TURKEY HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 148. UNITED ARAB EMIRATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 149. UNITED ARAB EMIRATES HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM HORMONAL CONTRACEPTIVES MARKET SIZE, BY HORMONE, 2018-2030 (USD MILLION)
• TABLE 151. UNITED KINGDOM HORMONAL CONTRACEPTIVES MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 152. UNITED KINGDOM HORMONAL CONTRACEPTIVES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 153. HORMONAL CONTRACEPTIVES MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 154. HORMONAL CONTRACEPTIVES MARKET, FPNV POSITIONING MATRIX, 2023

The Hormonal Contraceptives Market was valued at USD 17.19 billion in 2023, expected to reach USD 18.34 billion in 2024, and is projected to grow at a CAGR of 6.76%, to USD 27.19 billion by 2030.

The scope of the market for hormonal contraceptives encompasses various methods to prevent pregnancy by modulating hormone levels in the female body. This includes oral pills, injections, patches, vaginal rings, and implants. The application of hormonal contraceptives primarily targets birth control, but also offers benefits such as regulating menstrual cycles, managing conditions like polycystic ovary syndrome (PCOS), and reducing acne. End-use scope spans across individual consumers and healthcare facilities. Market growth is fuelled by increasing awareness of family planning, rising prevalence of menstrual-related disorders, and growing acceptance of modern contraceptive methods. Emerging opportunities lie in regions with unmet needs for contraceptive education and services, as well as in developing advanced delivery systems that minimize side effects. Companies focusing on innovation, such as non-invasive contraceptives and those with extended duration of effectiveness, could capture significant market share. Meanwhile, challenges include cultural and religious opposition, the need for consistent usage, side effects associated with hormonal methods, and competition from non-hormonal alternatives. Regulatory hurdles can also delay product launches and affect market dynamics. Limiting factors might involve price sensitivity in low-income regions and varying national policies affecting availability and approval. Technological advancements like personalized medicine and genetic profiling offer avenues for innovation, enabling targeted contraceptive solutions with optimized hormonal dosages, thereby improving effectiveness and reducing side effects. The market can benefit from insights into demographic trends, consumer behavior, and tailored marketing strategies. The nature of the hormonal contraceptives market is competitive and fast-evolving, requiring businesses to adapt rapidly to changing consumer preferences and scientific developments. Maintaining a balance between affordability, accessibility, and comprehensive educational campaigns about the benefits and drawbacks of hormonal contraception is crucial for sustainable growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hormonal Contraceptives Market

The Hormonal Contraceptives Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing cases of pregnancy-related health risks in women
  • Government initiatives to promote the use of contraceptives
  • Availability of oral contraceptives online
• Market Restraints
  • Side effects of hormonal contraceptives
• Market Opportunities
  • Research studies for producing highly effective contraceptive methods
  • Improving advertisements and marketing of hormonal contraceptives
• Market Challenges
  • Limited social acceptance of hormonal contraceptives

Porter's Five Forces: A Strategic Tool for Navigating the Hormonal Contraceptives Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hormonal Contraceptives Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hormonal Contraceptives Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hormonal Contraceptives Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hormonal Contraceptives Market

A detailed market share analysis in the Hormonal Contraceptives Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hormonal Contraceptives Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hormonal Contraceptives Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hormonal Contraceptives Market

A strategic analysis of the Hormonal Contraceptives Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hormonal Contraceptives Market, highlighting leading vendors and their innovative profiles. These include Afaxys Pharma, LLC, Agile Therapeutics, Amgen Inc., Bayer AG, Boehringer Ingelheim GmbH, Cipla Limited, Glenmark Pharmaceuticals Limited, HLL Lifecare Limited, Johnson & Johnson Services, Inc., Lupin Pharmaceuticals, Inc., Novartis AG, Pfizer, Inc., Piramal Group, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Hormonal Contraceptives Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Hormone, market is studied across Androgens, Antiandrogens, Estrogens, Gonadotropins, and Progestogens.
• Based on Method, market is studied across Combined Oral Contraceptives, Implanted Contraceptives, Injected Contraceptives, Intrauterine, Oral Contraceptives, Transdermal Patch, and Vaginal Ring.
• Based on End-user, market is studied across Ambulatory Surgical Centers, Gynecology Centers, Homecare, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing cases of pregnancy-related health risks in women
    • 5.1.1.2. Government initiatives to promote the use of contraceptives
    • 5.1.1.3. Availability of oral contraceptives online
  • 5.1.2. Restraints
    • 5.1.2.1. Side effects of hormonal contraceptives
  • 5.1.3. Opportunities
    • 5.1.3.1. Research studies for producing highly effective contraceptive methods
    • 5.1.3.2. Improving advertisements and marketing of hormonal contraceptives
  • 5.1.4. Challenges
    • 5.1.4.1. Limited social acceptance of hormonal contraceptives
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Hormonal Contraceptives Market, by Hormone

• 6.1. Introduction
• 6.2. Androgens
• 6.3. Antiandrogens
• 6.4. Estrogens
• 6.5. Gonadotropins
• 6.6. Progestogens

7. Hormonal Contraceptives Market, by Method

• 7.1. Introduction
• 7.2. Combined Oral Contraceptives
• 7.3. Implanted Contraceptives
• 7.4. Injected Contraceptives
• 7.5. Intrauterine
• 7.6. Oral Contraceptives
• 7.7. Transdermal Patch
• 7.8. Vaginal Ring

8. Hormonal Contraceptives Market, by End-user

• 8.1. Introduction
• 8.2. Ambulatory Surgical Centers
• 8.3. Gynecology Centers
• 8.4. Homecare
• 8.5. Hospitals & Clinics

9. Americas Hormonal Contraceptives Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Hormonal Contraceptives Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Hormonal Contraceptives Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Afaxys Pharma, LLC
• 2. Agile Therapeutics
• 3. Amgen Inc.
• 4. Bayer AG
• 5. Boehringer Ingelheim GmbH
• 6. Cipla Limited
• 7. Glenmark Pharmaceuticals Limited
• 8. HLL Lifecare Limited
• 9. Johnson & Johnson Services, Inc.
• 10. Lupin Pharmaceuticals, Inc.
• 11. Novartis AG
• 12. Pfizer, Inc.
• 13. Piramal Group
• 14. Sun Pharmaceutical Industries Ltd.
• 15. Teva Pharmaceutical Industries Ltd.